NAS:OKUR (USA)
Â
Class A Shares
$
7.43
-0.38 (-4.87%)
11:09 PM EST
Business Description
OnKure Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US68277Q1058
Share Class Description:
OKUR: Class A SharesDescription
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 115.29 | |||||
| Equity-to-Asset | 0.95 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate Estimate | 55.23 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.41 | |||||
| 9-Day RSI | 23.52 | |||||
| 14-Day RSI | 24.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 23.71 | |||||
| Quick Ratio | 23.71 | |||||
| Cash Ratio | 23.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 65.51 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -21.65 | |||||
| ROIC % | -231.46 | |||||
| ROC (Joel Greenblatt) % | -516.45 | |||||
| ROCE % | -22.32 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.34 | |||||
| Price-to-Tangible-Book | 1.34 | |||||
| EV-to-EBIT | -3.08 | |||||
| EV-to-Forward-EBIT | -0.34 | |||||
| EV-to-EBITDA | -3.42 | |||||
| EV-to-Forward-Revenue | 23.11 | |||||
| EV-to-FCF | -1.11 | |||||
| Price-to-Net-Current-Asset-Value | 1.35 | |||||
| Price-to-Net-Cash | 1.36 | |||||
| Earnings Yield (Greenblatt) % | -32.47 | |||||
| FCF Yield % | -20.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OKUR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OnKure Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.663 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 24.46 | ||
| 14-Day ATR ($) | 0.910568 | ||
| 20-Day SMA ($) | 8.3775 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 7.025 - 19.9992 | ||
| Shares Outstanding (Mil) | 13.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OnKure Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OnKure Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
OnKure Therapeutics Inc Frequently Asked Questions
What is OnKure Therapeutics Inc(OKUR)'s stock price today?
The current price of OKUR is $7.43. The 52 week high of OKUR is $20.00 and 52 week low is $7.03.
When is next earnings date of OnKure Therapeutics Inc(OKUR)?
The next earnings date of OnKure Therapeutics Inc(OKUR) is .
Does OnKure Therapeutics Inc(OKUR) pay dividends? If so, how much?
OnKure Therapeutics Inc(OKUR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers